3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Lymphoma, T-Cell
3
Recurrence
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Hematologic Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms, Plasma Cell
1
Lymphoma, T-Cell, Peripheral
1
Leukemia, Lymphoid
1
Hodgkin Disease
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Interventions
Cyclophosphamide
19
romidepsin
15
fludarabine phosphate
13
Whole-Body Irradiation
13
Peripheral Blood Stem Cell Transplantation
11
Mycophenolic Acid
11
Doxorubicin
11
Vincristine
10
Prednisone
10
Cyclosporine
10
10-propargyl-10-deazaaminopterin
10
Gemcitabine
8
Etoposide
8
Alemtuzumab
8
Bortezomib
6
Dexamethasone
5
Busulfan
5
Brentuximab Vedotin
5
mogamulizumab
4
denileukin diftitox
4
darinaparsin
4
Vitamin B 12
4
Nivolumab
4
Lenalidomide
4
Folic Acid
4
Carboplatin
4
carfilzomib
3
belinostat
3
Tacrolimus
3
Rituximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, T-Cell, Peripheral
×
duvelisib
×
Clear all
NCT03372057
2025-03-07
PRIMO
SecuraBio
Phase 2
Completed
156 enrolled
21 charts